Skip to Content
Merck
  • The effect of different amounts of calcium intake on bone metabolism and arterial calcification in ovariectomized rats.

The effect of different amounts of calcium intake on bone metabolism and arterial calcification in ovariectomized rats.

Journal of nutritional science and vitaminology (2013-03-29)
Umon Agata, Jong-Hoon Park, Satoshi Hattori, Yuki Iimura, Ikuko Ezawa, Takayuki Akimoto, Naomi Omi
ABSTRACT

Low calcium (Ca) intake is the one of risk factors for both bone loss and medial elastocalcinosis in an estrogen deficiency state. To examine the effect of different amounts of Ca intake on the relationship between bone mass alteration and medial elastocalcinosis, 6-wk-old female SD rats were randomized into ovariectomized (OVX) control or OVX treated with vitamin D(3) plus nicotine injection (VDN) groups. The OVX treated with VDN group was then divided into 5 groups depending on the different Ca content in their diet, 0.01%, 0.1%, 0.6%, 1.2%, and 2.4% Ca intakes. After 8 wk of experimentation, the low Ca intake groups of 0.01% and 0.1% showed a low bone mineral density (BMD) and bone properties significantly different from those of the other groups, whereas the high Ca intake groups of 1.2% and 2.4% showed no difference compared with the OVX control. Only in the 0.01% Ca intake group, a significantly higher Ca content in the thoracic artery was found compared with that of the OVX control. Arterial tissues of the 0.01% Ca intake group showed an increase of bone-specific alkaline phosphatase (BAP) activity, a marker of bone mineralization, associated with arterial Ca content. However, the high Ca intake did not affect arterial Ca content nor arterial BAP activity. These results suggested that a low Ca intake during periods of rapid bone loss caused by estrogen deficiency might be one possible cause for the complication of both bone loss and medial elastocalcinosis.

MATERIALS
Product Number
Brand
Product Description

Supelco
Cholecalciferol (D3), analytical standard
Sigma-Aldrich
Cholecalciferol, meets USP testing specifications
Sigma-Aldrich
Cholecalciferol, ≥98% (HPLC)
Sigma-Aldrich
Cholecalciferol, analytical standard
Cholecalciferol, European Pharmacopoeia (EP) Reference Standard
USP
Cholecalciferol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Vitamin D3 solution, 100 μg/mL in ethanol, 97% (CP)
Supelco
Cholecalciferol (Vitamin D3), Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Vitamin D3 solution, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®